Scientific rationale for combination immunotherapy of hepatocellular carcinoma with anti–PD-1/PD-L1 and anti–CTLA-4 antibodies
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
The outcomes of immune checkpoint inhibitor therapies against advanced cancer have greatly exceeded initial expectations since the early clinical studies reported in 2010 [1] and 2012 [2]. It is now evident that immune checkpoint inhibitors are highly effective against multiple solid tumors in addition to malignant melanoma, which was the first malignancy to be studied. Although researchers were initially skeptical about the practical use of conventional cancer immunotherapies that solely enhance immune responses, scientists in both industry and academia are vigorously pursuing the development of anticancer immunotherapies using immune checkpoint inhibitors. In fact, the journal Science designated cancer immunotherapy as the “Breakthrough of the Year” in 2013, and the journal Nature named immune checkpoint blockade in cancer a paradigm shift in cancer treatment. Since then, various industry-academia collaborations have been initiated, and the remarkable strides in this field have been hailed as “the dawn of the new cancer therapy era” [3] and the “renaissance of cancer immunotherapy” [4]. The first immune checkpoint molecule to be described, programmed cell death protein 1 (PD-1), was identified in 1992 by Dr. Tasuku Honjo and colleagues at Kyoto University [5]. Published online: September 27, 2019
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“To date, limited antitumor activity with ICI monotherapies and dual PD-(L)1 and CTLA-4 inhibitor regimens has been observed in pediatric solid tumors (3, 6–8, 10–12).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [12]
In the citing paper
“Because of the complementary mechanisms of action of durvalumab and tremelimumab, the combination of both agents may enable antitumor T cell responses that are not achieved with either agent alone (12, 13).”
From Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors (2026) · cites this paper as [12]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576
Self-citationEvolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 727
Neoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 284
Kudo, M. (2020) · Cancers · doi:10.3390/cancers12051089 · Cited by 197
“Furthermore, other phase III trials of combinations with CTLA-4 inhibitors [66] (durvalumab plus tremelimumab [HIMALAYA study] and nivolumab plus ipilimumab [the CheckMate 9DW study]) are currently being conducted (Figure 1 and Table 2).”
BackgroundSelf-citationPeng, Y., Liu, C., Li, M., Li, W., Zhang, M., Jiang, X. W., Chang, Y., Liu, L., Wang, F., & Zhao, Q. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01792-4 · Cited by 126
Emerging Immunotherapy Approaches for Advanced Clear Cell Renal Cell Carcinoma
Meng, L., Collier, K. A., Wang, P., Li, Z., Monk, P., Mortazavi, A., Hu, Z., Spakowicz, D. J., Zheng, L., & Yang, Y. (2023) · Cells · doi:10.3390/cells13010034 · Cited by 86
“CTLA-4 inhibitors constitute another class of checkpoint inhibitors that amplify anti-tumor immunity via CTLA-4 inhibition on T cells, with ipilimumab being a well-characterized example [32,33].”
BackgroundCombination of PD-1/PD-L1 and CTLA-4 inhibitors in the treatment of cancer – a brief update
Park, J., & Skålhegg, B. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1680838 · Cited by 69
Rager, T., Eckburg, A., Patel, M., Qiu, R., Gantiwala, S., Dovalovsky, K., Fan, K. D., Lam, K., Roesler, C., Rastogi, A., et al. (2022) · Cancers · doi:10.3390/cancers14153779 · Cited by 59
“Additional inhibition of the CTLA-4 pathway, on the other hand, causes increased activation of CD8-positive cells in lymph nodes and tumor cells [148] (Figure 3).”
BackgroundZhao, M., Huang, H., He, F., & Fu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188277 · Cited by 47
Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma
Alden, S. L., Lim, M., Kao, C., Shu, D. H., Singal, A. G., Noonan, A. M., Griffith, P., Baretti, M., Ho, W. J., Kamel, I. R., et al. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0072 · Cited by 43
“CTLA-4 expressed on T cells blunts the immune system’s response to tumor antigens by blocking binding of B7 on antigen-presenting cells (APC) to CD28 on T cells, resulting in suppression of APC function and impaired activation of CD8+ T cells (19).”
BackgroundLimited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Kudo, M. (2020) · Liver Cancer · doi:10.1159/000512170 · Cited by 38
Self-citationWalsh, R. J., & Tan, D. S. P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194523 · Cited by 36
“Simultaneous blockade of both PD1/PDL1 and CTLA-4 checkpoints thus seems a rational way to attempt to increase immune response and treatment efficacy [23].”
BackgroundSurveillance, Diagnosis, and Treatment Outcomes of Hepatocellular Carcinoma in Japan: 2021 Update
Kudo, M. (2021) · Liver Cancer · doi:10.1159/000516491 · Cited by 29
Self-citationBrackenier, C., Kinget, L., Cappuyns, S., Verslype, C., Beuselinck, B., & Dekervel, J. (2023) · Cancers · doi:10.3390/cancers15020348 · Cited by 30
“Therapeutic targeting of CTLA-4 releases the CTLA-4-dependent ‘brake’ on the immune system leading to more effective priming of T-cells by cancer antigens and restoring the balance between stimulatory and regulatory signals in the TME [73].”
BackgroundCancer combination therapies by silencing of CTLA‐4, PD‐L1, and TIM3 in osteosarcoma
Sorkhabi, A. D., Sarkesh, A., Fotouhi, A., Saeedi, H., & Maleki, L. A. (2022) · IUBMB Life · doi:10.1002/iub.2655 · Cited by 24
“Thus, it presents a rationale for incorporating CTLA-4 blockade to suppress the B7-CTLA-4 pathway in order to enhance CD8 T cell activation in lymph nodes and their subsequent infiltration into the tumor microenvironment, resulting in optimal PD-1/PD-L1 axis blockade.(29) CTLA-4 is an immune system negative regulator…”
BackgroundAlqahtani, S. A., Sanai, F. M., Alolayan, A. A. M., Abaalkhail, F. A., Alsuhaibani, H., Hassanain, M. M., Alhazzani, W. A., Alsuhaibani, A. A., Algarni, A. A., Forner, A., et al. (2020) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_477_20 · Cited by 28
“Simultaneous blocking of the CTLA‐4 pathway leads to priming and activation of cytotoxic T‐cells in the lymph nodes and improves the tumoral infiltration of cytotoxic T‐lymphocytes.[283] In this context, the combination of durvalumab (anti‐PD‐L1) and tremelimumab (anti‐CTLA‐4) induced an ORR of 15% with manageable AEs…”
BackgroundYang, H., Li, G., & Qiu, G.-P. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.726551 · Cited by 21
Progress in the application of hydrogels in immunotherapy of gastrointestinal tumors
Zheng, H., Li, M., Wu, L., Liu, W., Liu, Y., Gao, J., & Lu, Z. (2023) · Drug Delivery · doi:10.1080/10717544.2022.2161670 · Cited by 23
“A variety of tumors have been successfully treated by ICIs in recent years after they were developed and approved by the FDA (Kudo, 2019).”
BackgroundInfluentialChami, P., Diab, Y., Khalil, D. N., Azhari, H., Jarnagin, W. R., Abou‐Alfa, G. K., Harding, J. J., Hajj, J., Ma, J., Homsi, M. E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316773 · Cited by 20
Zhang, Q., Xiao, Z., Sun, S., Wang, K., Qian, J., Cui, Z., Tao, T., & Zhou, J. (2021) · Cancer Management and Research · doi:10.2147/cmar.s291811 · Cited by 19
Chu, H. H., Chun, S.-Y., Kim, J. H., Kim, P. H., Gwon, D. I., Ko, H. K., & Kim, N. (2020) · European Radiology · doi:10.1007/s00330-020-07536-8 · Cited by 18
“Recently, immunotherapy has emerged as a paradigm shift in cancer therapy [35, 36]Notably, the combination use of immune checkpoint inhibitor and anti-angiogenic drug has shown synergic benefits against advanced HCC [37–39] and may improve survival as a first-line therapy in patients with advanced HCC [37].”
BackgroundLi, W., Xu, M., Cheng, M., Wei, J., Zhu, L., Deng, Y., Guo, F., Bi, F., & Liu, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71065 · Cited by 21
“The process by which immune cells eliminate cancer cells, known as the cancer-immunity cycle, involves several stages: antigen recognition, T-cell activation, T-cell recruitment, and tumor cell killing [8–10].”
Rallis, K. S., Makrakis, D., Ziogas, I. A., & Tsoulfas, G. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i6.448 · Cited by 19
Peng, Q., Li, J., Wu, Q., Wang, P., Kang, Z., Deng, Y., Xiao, Y., Zheng, P., Ge, F., & Chen, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043155 · Cited by 17
Sensitizing the Efficiency of ICIs by Neoantigen mRNA Vaccines for HCC Treatment
Han, R., Wang, Y., & Lu, L. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics16010059 · Cited by 20
“For instance, one approach involves combining a PD-1 inhibitor with a CTLA-4 inhibitor, which has shown improved response rates and survival outcomes in clinical trials when compared to single-agent therapies [15].”
BackgroundProteogenomics offers a novel avenue in neoantigen identification for cancer immunotherapy
Ren, Y., Yue, Y., Li, X., Weng, S., Xu, H., Liu, L., Cheng, Q., Luo, P., Zhang, T., Liu, Z., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113147 · Cited by 17
Huang, C., Zhang, C., Sheng, J., Wang, D., Zhao, Y., Qian, L., Xie, L. Y., & Meng, Z. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.717319 · Cited by 15
“Clinically, recent literatures have proven the potential benefits of implementing immunotherapies in HCC (Kudo, 2019; Jiang et al., 2020a; Nishida and Kudo, 2020).”
BackgroundChan, L. L., & Chan, S. L. (2022) · Cancers · doi:10.3390/cancers14061526 · Cited by 16
“The addition of CTLA-4 inhibitor restores the costimulatory signal triggered by CD80/86-CD28 binding on T-cells and eliminates Tregs via antibody-dependent cytotoxicity to enhance the T-cells activation [44].”
BackgroundInfluentialBlockade of PD ‐1 and CTLA ‐4: A potent immunotherapeutic approach for hepatocellular carcinoma
Hou, K., Xu, X., Ge, X., Jiang, J., & Ouyang, F. (2023) · BioFactors · doi:10.1002/biof.2012 · Cited by 13
“95 Moreover, CTLA-4 expressed on Treg cells suppressed the antitumor effect in the microenvironment by infiltrating into tumors.”
BackgroundWerner, W., Kuzminskaya, M., Lurje, I., Tacke, F., & Hammerich, L. (2024) · Seminars in Liver Disease · doi:10.1055/a-2334-8311 · Cited by 15
“175 Furthermore, CTLA-4 blockade increases activation of CTL in the lymph node and therefore the probability of cancer antigen – speci fi c CTL in fi ltrating the TME 34 ( ► Fig.”
Immunotherapy for recurrent hepatocellular carcinoma
Bhatt, A., & Wu, J. J. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i15.2261 · Cited by 15
Yang, C., Zhang, M., Yao, Y., Wang, M., Zhong, X., Chen, Z., & Zhang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1657398 · Cited by 10
Considerations for individualized first-line systemic treatment in advanced hepatocellular carcinoma
Peeters, F., & Dekervel, J. (2023) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2023.102365 · Cited by 12
Treatment strategies in cervical cancer: treatment of advanced disease
Valdivia, A., Grau-Béjar, J. F., García-Durán, C., & Oaknin, A. (2022) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.34 · Cited by 11
Zhang, Y., Cui, X.-J., Xing, H., Ning, H.-F., Dong, P., & Wang, G. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2242384 · Cited by 11
“In the presence of antigen-specific CD8-positive T cells in tumor tissues, blocking the PD-1/PD-L1 pathway induces antitumor immunity and enhances the antitumor activity of effector T cells [45,46].”
BackgroundZhang, Z., Gao, W., Tan, X., Deng, T., Zhou, W., Jian, H., & Zeng, P. (2023) · BMC Cancer · doi:10.1186/s12885-023-10508-y · Cited by 9
“Study has shown that as Immune checkpoints, PD-1 or PD-L1 blocked have vastly improved the treatment of various cancers, including HCC [32].”
BackgroundWang, Y., Guo, J., Ma, D., Zhou, J., Yang, Y., Chen, Y., Wang, H., Sack, I., Li, R., & Yan, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.962272 · Cited by 8
Fujiwara, Y., Kuroda, H., Abe, T., Kakisaka, K., Nakaya, I., Ito, A., Watanabe, T., Yusa, K., Nagasawa, T., Sato, H., et al. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00458-7 · Cited by 6
“The combination therapy (Durva/Treme) has been shown to have an additive antitumor activity, which is associated with complementary immunostimulatory effects [8, 9].”
Emerging Therapies in Penile Cancer
Alencar, A. M., & Sonpavde, G. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.910335 · Cited by 11
“The combined therapy with two classes of checkpoint inhibitors, anti-PD-1/PD-L1 and anti-CTLA4 antibodies, can improve the response to immunotherapy, as the blockage of B7-CTLA-4 pathway leads to increased activation of CD8+ cells in the lymph nodes as well as increased infiltration of activated CD8+ T cells into the…”
BackgroundCheng, S., Li, B., Tang, L., Liu, S., & Xiao, J. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090992 · Cited by 6
Parizi, M. K., Matsukawa, A., Bekku, K., Klemm, J., Alimohammadi, A., Laukhtina, E., Karakiewicz, P. I., Chiujdea, S., Abufaraj, M. M., Krauter, J., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.11.001 · Cited by 6
Zhang, J.-S., Sun, Y.-D., Li, Y., & Han, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36388 · Cited by 5
“Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) and Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), which have become standard treatments, have significantly improved patient outcomes [29 – 31].”
BackgroundZheng, S.-S., Wu, J., Zhang, Z., Wu, Y., Chen, Y., Qian, S., & Zhang, B. (2025) · Journal of Hepatocellular Carcinoma · doi:10.2147/jhc.s512302 · Cited by 5
“22,23 Interestingly, our subgroup analysis suggested that the 6-week ipilimumab regimen might provide better outcomes than the 3-week regimen, although this did not reach statistical significance (P=0.12).”
InfluentialZhang, N., Liu, T., Luo, M., Hao, J., Qin, S., Zhang, Y., Wang, G., Chen, Y., Zhang, J., Gu, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3412 · Cited by 4
Farah, H., Abosaoda, M. K., Mousa, H. M., Jyothi, R., Priyadarshini‐Nayak, P., Janney-J, B., Singh, G., Singh‐Chauhan, A., & Kumar‐Mishra, M. (2026) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.70245 · Cited by 6
“Unlike traditional chemotherapy or targeted therapy that directly attack tumor cells, immunotherapy leverages an understanding of how cancer cells evade immune detection [19–21].”
Zheng, C., Peng, Y., Wang, H., Wang, Y., Liu, L., & Zhao, Q. (2023) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s397892 · Cited by 4
“In particular, inhibition of PD1/PD-L1 and CTLA-4 are the principal antibodies of ICIs at present.(5,6) These suggests that”
BackgroundWonglhow, J., Dechaphunkul, A., Sunpaweravong, P., Sathitruangsak, C., Pajareeyaphan, S., & Wetwittayakhlang, P. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.944002 · Cited by 4
“Combinations of CTLA-4 and PD-L1 inhibitors have demonstrated additive antitumor activities, associated with complementary immunostimulatory effects [28].”
BackgroundYe, X., Sun, Y., Yang, L., Chen, C., Li, S., Dong, S., Qin, X., Li, X., Liu, C., Huo, J., et al. (2025) · Chemical Engineering Journal · doi:10.1016/j.cej.2025.168488 · Cited by 3
Synergistic Strategies in Systemic Therapy for Advanced Hepatocellular Carcinoma
Yu, Y., Jiang, Y., Yang, Y., Glandorff, C., Fang, W., & Sun, M. (2025) · Global Challenges · doi:10.1002/gch2.202500247 · Cited by 7
“Therefore, combining anti-PD-1/PD-L1 and anti-CTLA-4 antibodies can relieve immunosuppressive effects at different stages of T cell immune responses [92].”
Majeed, A., Alaparthi, S. S., Halegoua-DeMarzio, D. L., Eberle-Singh, J. A., Jiang, W., Anne, P. R., Shah, A. P., Bowne, W. B., & Lin, D. (2024) · World Journal of Oncology · doi:10.14740/wjon1840 · Cited by 2
“Combinations of PD-1 and CTLA-4 inhibitors have demonstrated both significant anti-tumor and immunostimulatory effects in HCC [18, 19].”
BackgroundLiu, L., He, W., & Liu, J. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2024.102465 · Cited by 2
Wang, X., Huang, J., Liu, Y., Wu, L., Cai, R., Zheng, Q., & Li, L. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03797-0 · Cited by 2
“PD-1 PD-1/ PD-L1 inhibition alone cannot induce an effective antitumor response if effector T cells are not present in tumor tissues; therefore, combined inhibition of CTLA-4 may be necessary to ensure an inflamed tumor microenvironment [25].”
Zhao, Q., Ning, Y., Lin, K., Liu, X., Ding, Y., Jiang, X., Zhang, Z., Xuan, Y.-T., Liu, L., Wang, F., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1417814/v1 · Cited by 2
Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1680081 · Cited by 1
“Because of the complementary mechanisms of action of durvalumab and tremelimumab, the combination of both agents may enable antitumor T cell responses that are not achieved with either agent alone (12, 13).”
Wang, C.-H., Wang, H., Wang, X., Xing, X.-H., Wu, Y., Luo, M.-M., Pan, Y.-F., Dong, L., Tan, Y., Huang, H., et al. (2025) · Scientia Sinica Chimica · doi:10.1360/ssc-2025-0009 · Cited by 1
Tokumaru, T., Sakamoto, S., Tabuchi, M., Uemora, S., Tamura, S., Hirakawa, M., Kakizaki, M., & Okabayashi, T. (2025) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-025-02201-3 · Cited by 1
“Recently, combination therapy with cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-ligand 1 (PD-L1) inhibitors, known as the single tremelimumab regular interval durvalumab (STRIDE) regimen, was introduced as the standard treatment for HCC [1, 2].”
de Oliveira, M. C., Fortunato, G. M., da Silva, P. R., Pacheco, B. L. B., da Silva, M. R., & de Oliveira, K. B. (2025) · Discover Oncology · doi:10.1007/s12672-025-04179-3 · Cited by 2
“The combination of anti-CTLA-4 and anti-PD-L1 antibodies has shown additive antitumor effects based on complementary immunomodulatory mechanisms [113, 114].”
Pureur, D., & Edeline, J. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.03.011 · Cited by 1
Agranulocytosis Following Durvalumab Plus Tremelimumab Therapy for Hepatocellular Carcinoma
Uchida, G., Hiraga, J., Morita, K., Takeuchi, A., Takashi, H., Furune, S., & Tsuzuki, T. (2025) · Internal Medicine · doi:10.2169/internalmedicine.5910-25 · Cited by 1
Current and Future Scenario of Immunotherapy for the Treatment of Hepatocellular Carcinoma
Bhatt, S., Kanoujia, J., Dhar, A. K., Singh, R. K., & Rajangam, J. (2020) · Current Cancer Therapy Reviews · doi:10.2174/1573394716999200818103724
Emerging Role of Immune Therapy in HCC
Stein, S. (2021) · Digestive Disease Interventions · doi:10.1055/s-0041-1722932
Immunotherapy in Melanoma and Merkel Cell Cancer
Chow, M., Sangalang, E. A., Chow, C., & DAUD, A. I. (2022) · Springer eBooks · doi:10.1007/978-3-030-93084-4_67
Alden, S. L., Lim, M., Kao, C., Shu, D. H., Singal, A. G., Noonan, A. M., Griffith, P., Baretti, M., Ho, W. J., Kamel, I. R., et al. (2023) · doi:10.1158/2767-9764.c.6719612.v2
Леонидовна, Б. Е., Zolnikova, O. Y., & Paltzev, M. A. (2024) · Molekulyarnaya Meditsina (Molecular medicine) · doi:10.29296/24999490-2024-01-01
Peng, Y., Liu, C., Li, M., Li, W., Zhang, M., Jiang, X. W., Chang, Y., Liu, L., Wang, F., & Zhao, Q. (2021) · Figshare · doi:10.6084/m9.figshare.13889040
Tiemann, M., Samoilova, V. E., Atiakshin, D., Kostin, A. A., & Buchwalow, I. (2023) · Nature Cell and Science · doi:10.61474/ncs.2023.00013
Current update on pharmacological strategies of penile cancer
Deshmukh, S. S., Chaudhari, K. S., Basu, A., & Sonpavde, G. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2492335
“In such setting, addition of a VEGF inhibitor could augment the immunosuppressive effect of anti-PD-1/PD-L1 and anti-CTLA-4 drugs [57].”
Peng, Y., Liu, C., Li, M., Li, W., Zhang, M., Jiang, X., Chang, Y., Liu, L., Wang, F., & Zhao, Q. (2021) · Figshare · doi:10.6084/m9.figshare.13889037
Peng, Y., Liu, C., Li, M., Li, W., Zhang, M., Jiang, X., Chang, Y., Liu, L., Wang, F., & Zhao, Q. (2021) · Figshare · doi:10.6084/m9.figshare.13889034
Vemula, S. S. M., Abdelhakeem, A., Majeed, U., Onteddu, N. K. R., & Mosalem, O. M. (2026) · Livers · doi:10.3390/livers6050085
“Resistance to initial ICI therapy in HCC may arise through adaptive immune mechanisms and changes in the tumor microenvironment [35–37].”
Metadata
- Authors
- Kudo, M.
- Affiliations
- Kindai University Hospital (JP)
- Corresponding author
- Kudo, Masatoshi
- ORCID
- Kudo, Masatoshi
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2019
- Volume
- 8
- Issue
- 6
- Pages
- 413-426
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC6883444
- OpenAlex
- W2976901627
- Cited by
- 70
- References
- 54
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 9 · 2023: 18 · 2022: 11 · 2021: 10 · 2020: 5
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Liver Cancer (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- hepatocellular carcinoma, combination immunotherapy, anti-PD-1, PD-L1 inhibitors, anti-CTLA-4 antibody, immune checkpoint inhibitors, tumor immunology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.